A new meta-analysis published in the journal Psychopharmacology has found that individuals diagnosed with major depressive disorder tend to have lower levels of glutathione in a specific area of the brain known as the occipital cortex. The findings add to growing evidence linking depression to oxidative stress and suggest that brain antioxidants could play a role in understanding or potentially treating the disorder.
Major depressive disorder is a widespread mental health condition affecting hundreds of millions of people globally. It is associated with a wide range of symptoms, including persistent sadness, fatigue, loss of interest in previously enjoyable activities, and impaired cognitive and physical functioning.
Scientists have long investigated possible biological contributors to depression, including changes in neurotransmitter systems and immune activity. One area of increasing interest is the role of oxidative stress, which occurs when the body’s production of reactive molecules outpaces its antioxidant defenses.
Glutathione is the most abundant antioxidant found in the brain. It plays a central role in protecting brain cells from oxidative damage by neutralizing harmful molecules known as free radicals. When the balance between oxidative molecules and antioxidants is disrupted, cells can become damaged, potentially leading to or worsening a variety of diseases—including neuropsychiatric conditions like depression.
Several studies have suggested that individuals with depression may have lower levels of glutathione in the blood or in post-mortem brain tissue, but until now, it was unclear whether these differences could also be observed in living people using brain imaging techniques.
To investigate this question, a team of researchers conducted a meta-analysis—a method that combines the results of multiple studies to produce a more comprehensive and statistically reliable estimate of an effect. In this case, the researchers searched three scientific databases for studies that used a brain imaging technique called proton magnetic resonance spectroscopy to measure glutathione levels in people with depression and healthy individuals.
“The data out there on the role of oxidative stress in depression and other conditions is somewhat mixed, and the huge variety of modalities used to explore it means that it’s hard to see the wood for the trees. So in this study, we were keen to have a look at one particular modality – proton magnetic resonance spectroscopy – to see what the data showed,” said study author Charlie Bell, an honorary clinical lecturer at King’s College London and fellow in medicine at Girton College,
After screening a total of 178 publications, the researchers identified eight studies that met their inclusion criteria. These studies provided data from 230 people with major depressive disorder and 216 healthy controls. All participants had been assessed for depression based on widely used diagnostic systems, and studies had to provide enough data on glutathione levels to allow for statistical comparison.
The researchers focused on specific brain areas where at least three studies had been conducted: the occipital cortex and the medial frontal cortex. The occipital cortex is located at the back of the brain and is primarily involved in visual processing, while the medial frontal cortex is located near the front of the brain and is thought to play a role in emotion regulation and decision-making. Other brain areas were not included in the meta-analysis because too few studies were available for meaningful comparison.
The results showed that glutathione levels were lower in the occipital cortex of individuals with depression compared to healthy controls. The size of this difference was considered large by conventional standards.
In contrast, there were no significant differences in glutathione levels in the medial frontal cortex or when data from all brain areas were combined.
These findings suggest that the reduction in glutathione may be specific to the occipital region, at least based on current evidence. This regional difference is somewhat surprising, as most previous research has focused on the frontal areas of the brain in depression.
“As with so much in psychiatry, more work is needed,” Bell told PsyPost. “That said, we did see evidence that supported the role of oxidative stress in depression, and because of this, there may be stress-related pathways that we can target in the future, meaning new types of medication might be useful in major depression.”
The analysis did not find signs of publication bias, which increases confidence in the results. However, the authors acknowledged some limitations. First, the number of studies included was small, especially for brain regions outside of the occipital and medial frontal cortex. Some studies had to be excluded because they lacked necessary data or were available only in abstract form.
There was also variation in how glutathione was measured and analyzed across the studies. For example, some studies used different internal reference chemicals, which could influence the results.
“I was somewhat surprised by the sheer heterogeneity of the methodology used,” Bell said. “It’s hard to do useful comparisons when different groups use different experimental techniques or look at different regions of the brain.”
Another limitation was the lack of consistent data on clinical characteristics such as symptom severity, medication use, or comorbid conditions. These factors might affect glutathione levels but could not be examined in this meta-analysis. Additionally, the studies included participants with varying ages and durations of illness, which may contribute to differences in brain chemistry.
“There are really few studies available in this area, which is part of the reason our meta-analysis only gave a hint rather than anything definitive,” Bell explained.
Despite these limitations, the findings are consistent with the idea that oxidative stress is involved in depression and that glutathione plays an important role in brain health. The brain uses large amounts of oxygen and is particularly vulnerable to oxidative damage. If antioxidant defenses like glutathione are reduced, it could contribute to cellular stress and inflammation, which are increasingly recognized as factors in mental illness.
“It would be great to see groups really home in on specific brain regions and look at the role of oxidative stress in these – and it’s likely that there are a number of other conditions where a similar meta-analysis could yield results,” Bell said.
The study, “Glutathione alterations in depression: a meta-analysis and systematic review of proton magnetic resonance spectroscopy studies,” was authored by Charles J. M. Bell, Mitul Mehta, Luwaiza Mirza, Allan H. Young, and Katherine Beck.
